MediPharm’s Bleak Outlook; Cannabis Watchlist Updates – Money and Markets

In this week’s Marijuana Market Update, I provide some analysis on MediPharm Lab Corp.’s stock and have an update for the Cannabis Watchlist.

If you’ve been investing for any amount of time, you’ve run across a common saying as any stock takes a dive.

“Buy the dip,” investors of all kinds suggest.

It can be tempting, especially in an exciting and ever-changing market like cannabis, to take chances, to be risky and buy a dip in a stock. I’m not advising against that approach — I just want to make sure your approach is strategic.

Predicting the bottom for a stock is almost impossible. That’s why our strategy at Money & Markets is to target stocks in an uptrend.

In today’s Marijuana Market Update, I showcase a cannabis stock that highlights the risks of buying the dip.

I learned about this company from Melanie, who emailed me at feedback@moneyandmarkets.com.

She said:

Love your platform. Straight-forward information with no BS. Excellent job, and keep up the great work.

Would you mind looking into MediPharm Labs for us? It used to be a hot stock but it seems it has fallen off the radar totally.

Thank you!

-Melanie

Thank you for your email and kind comments, Melanie!

About MediPharm Labs Corp.

MediPharm Labs Corp. (OTC: MEDIF) is a Canada-based company that produces and sells pharmaceutical-grade cannabis oil and concentrates for derivative products in Canada and Australia.

It also provides contract-processing services to licensed cannabis producers and growers in Canada.

Melanie is right: The company fell off the radar after reaching highs in late 2019.

This is due, in part, to a drastic drop in revenue. The company‘s total revenue dropped 72% from 2019 to 2020.

MediPharm’s revenue went from $13.9 million in the second quarter

Read More Here...

Share on facebook
Share on twitter
Share on reddit
Share on pinterest
Share on email

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top